Citation Impact
1 from Science/Nature 59 standout
Citing Papers
Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy
2024 Standout
Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs
2024 Standout
Works of Carl Cook being referenced
Abstract CT013: A phase Ib, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD1775 monotherapy in patients with advanced solid tumors: initial findings
2016
A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors.
2016
Author Peers
| Author | Oncology | PRM | Molecular Biology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|
| Carl Cook | 89 | 40 | 58 | 12 | 133 | |
| Jeri Edwards | 1 | 4 | 7 | 245 | ||
| Keiko Takata | 41 | 27 | 112 | 15 | 485 | |
| P. Schlichting | 4 | 2 | 35 | 18 | 895 | |
| M. N. Cleary | 1 | 1 | 5 | 198 | ||
| Rob E. Poelmann | 11 | 154 | 291 | 9 | 704 |
All Works
Login with ORCID to disown or claim papers
Loading papers...